about
Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model.A systematic review of risk factors associated with surgical site infections among surgical patientsSafety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy AdultsMAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virusInfliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.A pilot clinical trial of a recombinant ricin vaccine in normal humans.Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity.Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia.Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database.Antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis.Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse modelRespiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model.Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.Staphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893Respiratory syncytial virus persistence: evidence in the mouse model.The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.Antibody-based therapy to combat Staphylococcus aureus infections.Safety experience with caspofungin in pediatric patients.Herpes simplex virus encephalitis during suppressive therapy with acyclovir in a premature infant.The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia.Alternatives to antibiotics.Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants.Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.Respiratory Syncytial Virus Genotypes, Host Immune Profiles and Disease Severity in Young Children Hospitalized with Bronchiolitis.Effect of dexamethasone on respiratory syncytial virus-induced lung inflammation in children: results of a randomized, placebo controlled clinical trial.Diagnostic virology practices for respiratory syncytial virus and influenza virus among children in the hospital setting: a national survey.Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections.A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.
P50
Q24811196-C24A331B-37A2-4E38-B9F3-15E976A5F1BFQ26850029-CCE4C6CD-8E43-42DD-9B36-6E17C6131EABQ28354370-108D72D7-2173-4AE4-8929-DD53E3506634Q28593715-D0B05F45-2E6B-4715-A65A-95A4AFE5DEB4Q33798966-918B957C-046D-407B-99F6-03E07F3F32DBQ34123608-D4F0050F-7EA5-4B7D-A745-FB4444EC208BQ34150923-C4E973DC-EFAA-4D36-9D68-89AEDB1A66CAQ34335695-B18869D7-A643-46EF-A3B6-0CBEEB6C023EQ34479216-2A2D4A28-C624-4454-AFAC-9C591D4780D8Q34726089-694156E1-1752-4246-84F4-1393124F37EDQ34726240-C289FE67-038F-48EB-A13E-CC49E88BC8A4Q34916584-63A52B6B-2F1D-4239-B2DB-4F8A7084590DQ35669486-2235757F-1B2C-4504-AA0F-96CC0341EAC3Q36284981-0EC74CA7-5B03-431B-86C0-2A23721894C7Q36419843-FF0D6885-4FA2-475F-9703-4C8929722CEDQ36946801-9BF588C2-CA70-4B13-8953-EE866D56F094Q37016967-B25FFF7C-AEDD-4180-A222-F08D28CC944EQ37115709-FEEE2151-B444-4671-9C76-A7174541B0A0Q37203734-48FB729C-DFBA-4E1A-891D-93106826D176Q37280556-3902FD9E-B514-4EC6-B1C5-15177B9A9812Q38633668-2DE11CEF-A9F7-4AFD-A2F9-BEE47E7D8E7EQ39478796-2033B0F8-F06A-45DD-9D5A-F35089109283Q40302465-FC9D4A4D-F4B3-49E3-B7A3-A2987A224CAAQ40378992-9B0F7484-7554-41A1-8F88-110F7084D8C3Q40513915-C3ED7324-AA1E-47AE-AA18-23886F4A5BC0Q40591899-4C16691D-3BBA-4814-AE83-5B3BEF83567CQ40733237-734F5DD4-803D-4BD1-B71E-5A1981F1ECB7Q40933391-4E6E6320-63B2-42AD-ADE4-EDDCFF564D44Q43868335-4F42418B-1F2D-4189-92A0-0B9D2575141DQ44227981-1A8C7671-4299-4715-B7CA-9104C63C9B99Q44880088-9849B896-FF46-47E9-BC24-51711D76C789Q45015455-17DEBAC7-22AA-4263-AEED-4E1912315D4EQ45326129-ABB4B8F7-C0EC-4726-B175-A37CD00EAD43Q45385048-78763C05-D452-4B71-A63C-2CF35717898CQ45399900-9549A50F-4968-47E1-82CD-D107DE2C4DDCQ45504067-83B1416E-97FE-44D1-A12D-C70AE47DE9F9Q46103005-146D9601-EB80-414C-A7D3-AEB2D89EFE7DQ46720912-C73E1B71-46D3-4866-A033-00EB7D5B5FE6Q54574152-7E53BCB9-BAEB-497A-9029-4CBA796B3307
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hasan Jafri
@ast
Hasan Jafri
@en
Hasan Jafri
@es
Hasan Jafri
@nl
Hasan Jafri
@sl
type
label
Hasan Jafri
@ast
Hasan Jafri
@en
Hasan Jafri
@es
Hasan Jafri
@nl
Hasan Jafri
@sl
prefLabel
Hasan Jafri
@ast
Hasan Jafri
@en
Hasan Jafri
@es
Hasan Jafri
@nl
Hasan Jafri
@sl
P106
P31
P496
0000-0003-2179-6450